g protein-coupled receptor News
-
Immune Biosolutions selected for JLABS @ Toronto
Immune Biosolutions selected for JLABS @ Toronto Immune Biosolutions is among the 22 growing businesses selected for JLABS @ Toronto. Initiated and managed by the pharmaceutical company Johnson & Johnson, JLABS are a network of 6 tech incubators focusing on life sciences. The newest facility, JLABS @ Toronto, located in the MaRS district, is the first located outside the US. JLABS ...
-
Orion Biotechnology Presenting New Data at the GPCR Drug Discovery Summit
Orion Biotechnology Canada Ltd, a clinical stage company unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs), today announced that it will be presenting important new data at the GPCRs-Targeted Drug Discovery Summit, taking place this week – March 22-24, 2022. Dr. Hartley, Orion’s Vice-President Drug Discovery, will provide a presentation regarding ...
-
Orion Shares New Data on its Latest Best-in-Class Drug Candidate
Orion Biotechnology Canada Ltd, a drug discovery and development company unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs), today announced that it will be presenting important new data at both LSX World Congress and TIDES USA 2022 conference, taking place this week – May 10-12, 2022. Dr. Oliver Hartley, Orion’s Vice-President Drug Discovery, will present ...
-
Orion Receives Funding to Advance its Lead GPCR-Targeted Therapeutic
Orion Biotechnology Canada Ltd., a clinical stage company unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs) with a novel drug modality, proven discovery platform and best-in-class molecules, today announced that it is receiving advisory services and conditional funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). The ...
-
Endosomal Signaling Of Delta Opioid Receptors Is An Endogenous Mechanism And Therapeutic Target For Relief From Inflammatory Pain
Whether G protein-coupled receptors signal from endosomes to control important pathophysiological processes and are therapeutic targets is uncertain. We report that opioids from the inflamed colon activate δ-opioid receptors (DOPr) in endosomes of nociceptors. Biopsy samples of inflamed colonic mucosa from patients and mice with colitis released opioids that activated DOPr on nociceptors to ...
-
Confo Therapeutics Enters Collaborative Agreement With Regeneron
Ghent, Belgium – November 30, 2021 – Confo Therapeutics today announced that it has entered into a collaborative agreement with Regeneron Pharmaceuticals, Inc. whereby Confo’s technology platform, which uses conformationally selective VHH antibodies – ConfoBodies® – to stabilize GPCRs (G protein-coupled receptors) in disease-relevant conformations, will be ...
-
Profacgen Updated Its Membrane Protein Modeling Service Recently
Profacgen, a state-of-the-art protein service provider that provides custom protein services in the biological sciences, recently updated its membrane protein modeling service to better assist scientists in the field of structure-based protein engineering. Membrane proteins account for one third of all genes in the human genome, and they play critical roles as receptors, enzymes, ion channels, ...
By Profacgen
-
Orion Completes Lead Optimization of its CCR2-Targeted Molecule in Only 6 Months!
Orion Biotechnology, a clinical stage company unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs) with a novel drug modality, proven discovery platform and best-in-class molecules, today announced the successful completion of its OB-004 lead optimization. OB-004 is a GPCR targeted protein analog of CCL2 that targets the CCR2 receptor. The CCL2/CCR2 pathway plays an ...
-
Confo Therapeutics Expands Patent Estate For ConfoBody®-Based GPCR Screening Platform
Ghent, Belgium, December 15, 2021 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that it has extended its patent estate with four key US and EU patents granted as part of the company’s foundational “Steyaert patents”. The newly added patents (US-11,162,953, US-11,162,954, EP 3557254 and EP ...
-
Profacgen Helps Accelerate GPCR Study with Various Services
Profacgen, a global provider of drug screening and profiling services that offers a comprehensive panel of services designed to speed and simplify drug discovery research, now offers professional high-throughput GPCR screening services for identification of potential GPCR-targeting drugs. G protein-coupled receptors (GPCRs) are also known as seven-transmembrane domain receptors. They are ...
By Profacgen
-
Exosome Display Technology for Antibody Generation, Targeted Delivery, and Protein Array Screen
Scientists now have realized that exosomes, representing a novel mode of intercellular communication, contribute to a wide range of biological processes in health and disease including cancer. Especially, growing evidence shows that tumor-derived exosomes play critical roles in cancer. Exosomes and their cargos may serve as cancer prognostic markers, therapeutic targets or even as anticancer ...
-
Sosei Heptares and Kallyope Enter Collaboration to Identify and Validate Novel Gastrointestinal GPCR Targets for Drug Discovery
Sosei Group Corporation (“Sosei Heptares”; TSE: 4565), the international biopharmaceutical company, and New York City-based Kallyope, pioneers in drug discovery involving the gut-brain axis, have entered a strategic research collaboration to identify and validate novel G protein-coupled receptor (GPCR) targets with a goal of creating new drug discovery programs in the area of ...
-
Orbit Discovery awarded Innovate UK grant to expand high throughput cell-based functional screening platform capabilities in peptide drug discovery
Oxford, United Kingdom, 13th June, 2022: Orbit Discovery Ltd., (“Orbit”) a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, has been awarded a Smart grant by Innovate UK, the UK’s innovation agency. Totalling £472,000, the grant will facilitate the ...
-
Exosome Targeting Services at Creative Biolabs Ready to Boost Drug Delivery Research
Exosomes are picking up steam among scientists because they can perform a role in the immune response, antigen presentation, cell migration, cell differentiation, and tumor invasion. Exosomes, which provide a mechanism for macromolecules to be exchanged between cells, play a part in the development of various illnesses, particularly in the modulation of the cancer microenvironment and immune ...
-
Orion Biotechnology & Peptilogics Enter Strategic Research Collaboration to Enable AI-driven GPCR drug discovery
Orion Biotechnology Canada Ltd, a drug discovery company targeting previously undruggable G Protein-Coupled Receptors (GPCRs), and Peptilogics, a biotech company engineering peptide therapeutics by combining computation and biology to improve the treatment landscape for patients with life-threatening diseases, announced today that they have entered a research and development collaboration to ...
-
Confo Therapeutics Awarded EUR 1M VLAIO Grant For Pre-Clinical Development Of CFTX-1554, An AT2R Modulator For The Treatment Of Neuropathic Pain
Confo Therapeutics Awarded EUR 1M VLAIO Grant for Pre-Clinical Development of CFTX-1554, an AT2R Modulator for the Treatment of Neuropathic Pain Ghent, Belgium – March 30, 2021 – Confo Therapeutics announced today that it has been awarded a EUR 1 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant will support the pre-clinical development of CFTX-1554, ...
-
Creative Proteomics Introduces Mature Solutions for Membrane Protein Identification
Creative Proteomics, a globally recognized leader in proteomics services, is excited to introduce its latest pioneering achievement in the field of membrane protein identification. This suite of solutions promises to reshape the scientific landscape, empowering researchers and scientists with advanced tools to unlock the secrets of membrane proteins. Membrane proteins, central to a wide range ...
-
CD BioSciences Introduces New GPCR Purification Service for GPCR Research and Drug Development
CD BioSciences, a leading customer-focused biotechnology company based in New York, introduces new GPCR purification services to support and facilitate GPCR research and drug development. CD BioSciences has built an unparalleled GPCR purification platform to provide the most reliable service for researchers. With more than 800 members, G protein-coupled receptors (GPCRs) constitute the largest ...
-
CD BioSciences Introduces GPCR Drug Discovery Services
CD BioSciences, a leading customer-focused biotechnology company based in New York, recently introduces a series of GPCR Drug Discovery services to customers in their GPCR drug discovery and development projects. G protein-coupled receptors (GPCRs), also known as seven-(pass)-transmembrane domain receptors, play a pervasive physiological and pathophysiological role in humans. They are major ...
-
CD Bioparticles Expands Lipid System Portfolio by the Launch of Sphingolipids
CD Bioparticles, a leading manufacturer and supplier of various drug delivery products and services, has now expanded lipid system portfolio and launched a series of Sphingolipids products to support customers' scientific research. CD Bioparticles now offers more choices for researchers to choose from and use in lipid system applications, such as Ceramides, Sphingosines, Sphingomyelin, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you